Federica Di Nicolantonio
Federica Di Nicolantonio
University of Torino, Dept of Oncology & Candiolo Cancer Institute, FPO - IRCCS
Verified email at unito.it - Homepage
TitleCited byYear
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ...
18002008
Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR
A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ...
Nature 483 (7387), 100, 2012
13542012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532, 2012
12602012
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ...
The lancet oncology 6 (5), 279-286, 2005
10412005
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies
S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ...
Cancer research 67 (6), 2643-2648, 2007
9052007
Liquid biopsy: monitoring cancer-genetics in the blood
E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli
Nature reviews Clinical oncology 10 (8), 472, 2013
8822013
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ...
Cancer research 69 (5), 1851-1857, 2009
7602009
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ...
Jama 304 (16), 1812-1820, 2010
6692010
Biomarkers predicting clinical outcome of epidermal growth factor receptor–targeted therapy in metastatic colorectal cancer
S Siena, A Sartore-Bianchi, F Di Nicolantonio, J Balfour, A Bardelli
Journal of the National Cancer Institute 101 (19), 1308-1324, 2009
6022009
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D CorÓ, ...
Cancer discovery 1 (6), 508-523, 2011
5912011
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795, 2015
5092015
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma
C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ...
Nature 508 (7494), 118, 2014
4632014
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
4402013
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
F Di Nicolantonio, S Arena, J Tabernero, S Grosso, F Molinari, ...
The Journal of clinical investigation 120 (8), 2858-2866, 2010
3172010
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, ...
PloS one 4 (10), e7287, 2009
2732009
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution
S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli
Cancer discovery 4 (11), 1269-1280, 2014
2252014
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
1962014
Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer
M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ...
Cancer discovery 6 (2), 147-153, 2016
1782016
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ...
Cell reports 7 (1), 86-93, 2014
1672014
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer
F Molinari, L Felicioni, M Buscarino, S De Dosso, F Buttitta, S Malatesta, ...
Clinical Cancer Research 17 (14), 4901-4914, 2011
1582011
The system can't perform the operation now. Try again later.
Articles 1–20